Skip to content

Author

J. Hasenkamp

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Allogeneic hematopoietic cell transplantation for therapy-related hematological malignancies in patients with multiple myeloma

Improved survival in multiple myeloma (MM) patients after high-dose chemotherapy, autologous hematopoietic cell transplantation (auto-HCT), and novel agents has led to an increasing incidence of therapy-related hematological malignancies (t-HM), although optimal management remains unclear, particularly the role of allo...

M. Maulhardt, A. Angleitner, J. Büntzel et al. · 0 citations
Open access Aug 2026

Allogeneic stem cell transplantation after myeloablative conditioning with fludarabine, thiotepa, and cyclophosphamide in relapsed or refractory aggressive B-cell and T-cell lymphomas: results of the prospective ASTRAL study.

The data suggest that alloSCT can be effective after CART failure, with more than one-third of patients being in remission after two years, and these findings support the continued use of alloSCT in patients with aggressive lymphomas.

A. O. Saidy, B. Altmann, P. van Heteren et al. · 0 citations
Open access Aug 2026

In Search of Long-Term Disease Control: CAR T-Cell Therapy With Axicabtagene Ciloleucel or Allogeneic Hematopoietic Cell Transplantation Against Relapsed/Refractory Large B-Cell Lymphoma.

In conclusion, axi-cel provided superior PFS and OS to patients with r/r LBCL compared with allo-HCT, primarily due to lower treatment-related mortality and improved disease control in patients with chemorefractory disease prior to cellular therapy.

M. Maulhardt, Lina J. Kolloch, G. Westhofen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.